As the fight against Covid-19 edges on with the rapidly spreading Delta variant spreads globally, there is an increased interest from investors in Covid-19 related technology. This include diagnostics and vaccines. In the U.S., DNANudge Ltd., a maker of rapid Covid tests that were adapted on the fly from a consumer dietary-guidance technology, has received $60 million in funding led by Ventura Capital in a bid to ramp up production and expand diagnostic applications.
DNANudge will use the funding, which includes participation by Bank Julius Baer, to make more cartridges for its portable devices, which can diagnose Covid in about an hour, founder Christofer Toumazou said in an interview. The company is also making cartridges for cancer testing and consumer skin-care products.
2021 among seven hottest years on record
Djokovic has majority stake in biotech firm developing COVID-19 drug
Digital Services Act in the European Union, What You Need to Know
The Best Time to be on YouTube is Now: YouTube Boasts $30 Billion in Payments.
Insight into South African Entrepreneur
10 steps before considering dismissal for vaccine refusal
Breaking News1 month ago
Third Dose Neutralizes Omicron Variant Accordint to Pfizer and BioNTech
Covid-191 month ago
South Africa Records Highest Covid-19 Cases Since Omicron Find
Africa1 month ago
President Ramaphosa tests positive for Covid With Mild Symptoms.
USA4 weeks ago
US. FDA Authorizes First Oral Antiviral for Treatment of COVID-19